Stocks analysis

ABBV vs AKAM Stock Comparison

Scores Breakdown

Metric ABBV AKAM
📈 Growth 26/30 22/30
💰 Profitability 18/20 17/20
🏦 Financial Health 6/20 17/20
💵 Valuation 12/20 16/20
⚠️ Risk (lower is better) 8/10 4/10
Overall Score 64/100 78/100

Side-by-Side Summaries

ABBV Analysis AKAM Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

  • Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
  • Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over the 8 quarters, AKAM's revenues rose from about $1.00B to about $1.10B, a modest expansion of ~9-10%, with a steady uptrend across quarters. Net income moved from roughly $58M in 2024-Q3 to a peak of about $140M in 2025-Q3, before printing around $79M in 2026-Q2, reflecting quarterly volatility but positive trajectory.

💰 Margins & Cash Flow

Gross margin stayed robust in the mid-to-high 50s% (Q2 2026 ~55.8%; Q4 2025 ~58.6%; Q3 2025 ~59.2%). Operating income remained positive in every quarter shown. Operating cash flow (continuing) was solid, e.g., around $326M in 2026-Q2. Net cash flow turned positive in 2026-Q2 at roughly $0.85B, with investing cash outflows offset by financing inflows in several quarters, indicating healthy cash generation despite capex.

🛡️ Balance Sheet & Liquidity

Assets near $15.1B in 2026-Q2, liabilities around $10.3B, and equity about $4.75B. Current assets vs current liabilities yield a comfortable liquidity cushion (approx. 1.6x). Leverage remains moderate with substantial noncurrent assets and conservative equity backing.

⚠️ Key Drivers & Risks

  • Drivers: AI/Data Center edge/CDN demand; sustained enterprise traffic growth.
  • Risks: Revenue cyclicality and competition; valuation sensitive to margin shifts and growth pace.